Earnest Partners LLC Has $64.44 Million Holdings in Mednax, Inc (MD)

Earnest Partners LLC lifted its position in shares of Mednax, Inc (NYSE:MD) by 0.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,494,374 shares of the company’s stock after acquiring an additional 11,037 shares during the period. Earnest Partners LLC owned approximately 1.60% of Mednax worth $64,437,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Pacer Advisors Inc. increased its position in shares of Mednax by 8.1% during the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after acquiring an additional 145 shares in the last quarter. Commonwealth Bank of Australia increased its position in shares of Mednax by 15.3% during the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after acquiring an additional 293 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Mednax during the third quarter valued at approximately $103,000. Daiwa Securities Group Inc. increased its position in shares of Mednax by 20.0% during the second quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock valued at $181,000 after acquiring an additional 500 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Mednax during the second quarter valued at approximately $217,000. 98.48% of the stock is owned by institutional investors.

MD has been the topic of several research reports. KeyCorp set a $51.00 target price on shares of Mednax and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group restated a “hold” rating and issued a $44.00 target price on shares of Mednax in a report on Friday, November 3rd. Robert W. Baird restated a “hold” rating and issued a $47.00 target price on shares of Mednax in a report on Sunday, September 3rd. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, BMO Capital Markets initiated coverage on shares of Mednax in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price on the stock. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $53.22.

In other news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at approximately $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the transaction, the director now owns 44,215 shares in the company, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

Shares of Mednax, Inc (NYSE MD) traded up $0.79 during mid-day trading on Friday, reaching $51.64. 1,200,000 shares of the company traded hands, compared to its average volume of 2,049,669. Mednax, Inc has a 52 week low of $40.56 and a 52 week high of $72.13. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $4,836.34, a PE ratio of 15.79, a P/E/G ratio of 1.66 and a beta of 0.40.

Mednax (NYSE:MD) last issued its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.87. The company had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company posted $1.09 earnings per share. analysts predict that Mednax, Inc will post 3.1 EPS for the current year.

WARNING: This story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://weekherald.com/2017/12/10/earnest-partners-llc-has-64-44-million-holdings-in-mednax-inc-md.html.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply